Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)

Welcome to UK

Select your profile to continue on our website

Please read the important information below before continuing to our website

Please read the important information below before continuing to our website.

By clicking on your client type to enter the website, you are confirming that you have read and understood the important information that is contained below, and you accept the terms of the Privacy and Cookies policy.

THIS WEBSITE IS AIMED AT PROFESSIONAL CLIENTS IN THE UK

The information on this website is published in the UK by Lyxor Asset Management UK LLP (Lyxor UK), which is authorized by Financial Conduct Authority in the UK, under FCA Registration Number 435658.

The website is hosted by on Microsoft Azure servers.

This website is subject to French law and English Law

A professional client is a client that is either a per se professional client or an elective professional client (Note article 4 (1) 12 of Mifid )

A professional client is one of the following:

– an entity required to be authorised or regulated to operate in the financial markets. The following list includes all authorised entities carrying out the characteristic activities of the entities mentioned, whether authorised by an EEA State or a third country and whether or not authorised by reference to a directive:

a credit institution
an investment firm
any other authorised or regulated financial institution
an insurance company
a collective investment scheme or the management company of such a scheme
a pension fund or the management company of a pension fund
a commodity or commodity derivatives dealer
a local
any other institutional investor

– in relation to MiFID or equivalent third country business, a large undertaking, meeting two of the following size requirements on a company basis:

balance sheet total of EUR 20,000,000
net turnover of EUR 40,000,000
own funds of EUR 2,000,000

– in relation to business that is neither MiFID or equivalent third country business, a large undertaking meeting either of the following conditions:

a body corporate (including a limited liability partnership) which has (or any of whose holding companies or subsidiaries has) called up share capital of at least £10 million (or its equivalent in any other currency at the relevant time)
a large undertaking that meets (or any of whose holding companies or subsidiaries meets) two of the following tests: (i) a balance sheet total of EUR 12,500,000; (ii) a net turnover of EUR 25,000,000; (iii) an average number of employees during the year of 250
a national or regional government, a public body that manages public debt, a central bank, an international or supranational institution (such as the World Bank, the IMF, the ECP, the EIB) or another similar international organisation.
another institutional investor whose main activity is to invest in financial instruments (in relation to the firm's MiFID or equivalent third country business) or designated investments (in relation to the firm's other business). This includes entities dedicated to the securitisation of assets or other financing transactions.

The above definition is only an extract and is not exhaustive. For further details please refer to the Glossary section of the FSA Handbook: http://fsahandbook.info/FSA/html/handbook/Glossary/P

Lyxor and Lyxor ETF are names used by Lyxor Asset Management UK LLP to promote the products of Lyxor International Asset Management. Although information contained herein is from sources believed to be reliable, Lyxor Asset Management UK LLP makes no representation or warranty regarding the accuracy of any information. Any reproduction, disclosure or dissemination of these materials is prohibited.

Marketing Restrictions and Implications

Lyxor UCITS compliant Exchange Traded Funds (Lyxor UCITS ETFs) referred to on this website are open ended mutual investment funds (i) established under the French law and approved by the Autorité des Marchés Financiers (the French Financial Markets Authority), or (ii) established under the Luxembourg law and approved by the Commission de Surveillance du Secteur Financier (the Luxembourg Financial Supervisory Committee). Most, if not all, of the protections provided by the UK regulatory system generally and for UK authorised funds do not apply to these exchange traded funds (ETFs). In particular, investors should note that holdings in this product will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme in France.

This website is exclusively intended for persons who are not "US persons", as such term is defined in Regulation S or the US Securities Act 1933, as amended, and who are not physically present in the US. This website does not constitute an offer or an invitation to purchase any securities in the United States or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. Potential users of this website are requested to inform themselves about and to observe any such restrictions.

Index Replication Process

Lyxor UCITS ETFs follow both physical and synthetic index replication process.

However, most Lyxor UCITS ETFs follow synthetic replication process. This consists of entering into a derivative transaction (a ‘Performance Swap’, as defined below) with a counterparty that provides complete and effective exposure to its benchmark index. Lyxor has adopted this methodology in order to minimise tracking error, optimise transaction costs and reduce operational risks.

A Performance Swap is a contractual agreement which is negotiated over-the-counter (OTC) between two parties: the Lyxor UCITS ETF and its counterparty. From a risk perspective, each Performance Swap ranks equally with other senior unsecured obligations of the counterparty, such as common bonds (i.e., same rights to payments). In the Performance Swap, the counterparty of the Lyxor UCITS ETF commits to pay the Lyxor UCITS ETF a variable return based on a pre-determined benchmark index, instead of a fixed stream of income (as in bonds). At the same time, the counterparty will receive from the Lyxor UCITS ETF the performance and any related revenues generated by the basket's assets (excluding the value of the Performance Swap) held by the Lyxor UCITS ETF. Information provided on individual ETFs includes data on the basket relating to the ETF and the percentage value of the basket represented by each asset. The information is relevant to the closing values on the date given.

Investment Risks

The Lyxor UCITS ETFs described on this website are not suitable for everyone. Investors' capital is at risk. Investors should not deal in this product unless they understand, having obtained independent professional advice where necessary, its nature, terms and conditions, and the extent of their exposure to risk. The value of the product can go down as well as up and can be subject to volatility due to factors such as price changes in the underlying instrument and interest rates. If a fund is quoted in a different currency to the index, currency risks exist.

Prior to any investment in any Lyxor UCITS ETF, you should make your own appraisal of the risks from a financial, legal and tax perspective, without relying exclusively on the information provided by us. We recommend that you consult your own independent professional advisors (including legal, tax, financial or accounting advisors, as appropriate).

Specific Risks

· Capital at Risk. ETFs are tracking instruments: Their risk profile is similar to a direct investment in the Benchmark Index. Investors’ capital is fully at risk and investors may not get back the amount originally invested. Investments are not covered by the provisions of the Financial Services Compensation Scheme (“FSCS”), or any similar scheme.

· Counterparty Risk. Investors may be exposed to risks resulting from the use of an OTC Swap with Societe Generale. Physical ETFs may have Counterparty Risk resulting from the use of a Securities Lending Programme.

· Currency Risk. ETFs may be exposed to currency risk if the ETF or Benchmark Index holdings are denominated in a currency different to that of the Benchmark Index they are tracking. This means that exchange rate fluctuations could have a negative or positive effect on returns.

· Replication Risk. ETFs are designed to replicate the performance of the Benchmark Index. Unexpected events relating to the constituents of the Benchmark Index may impact the Index provider’s ability to calculate the Benchmark Index, which may affect the ETF’s ability to replicate the Benchmark Index efficiently. This may create Tracking Error in the ETF.

· Underlying Risk. The Benchmark Index of a Lyxor ETF may be complex and volatile. When investing in commodities, the Benchmark Index is calculated with reference to commodity futures contracts which can expose investors to risks related to the cost of carry and transportation. ETFs exposed to Emerging Markets carry a greater risk of potential loss than investment in Developed Markets as they are exposed to a wide range of unpredictable Emerging Market risks.

· Liquidity Risk. On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the Benchmark Index tracked by the ETF; a failure in the systems of one of the relevant stock exchanges, Societe Generale or other Market Maker systems; or an abnormal trading situation or event.

The securities can be neither offered in nor transferred to the United States.

Tax

Any statement in relation to tax, where made, is generic and non-exhaustive and is based on our understanding of the laws and practice in force as of the date of this document and is subject to any changes in law and practice and the interpretation and application thereof, which changes could be made with retroactive effect. Any such statement must not be construed as tax advice and must not be relied upon. The tax treatment of investments will, inter alia, depend on an individual’s circumstances. Investors must consult with an appropriate professional tax adviser to ascertain for themselves the taxation consequences of acquiring, holding and/or disposing of any investments mentioned on this website.

Further information on the risk factors are available in the [Risk Warning – link to risk page] section of the website.

Any fund prospectus and supplements are available at www.lyxoretf.co.uk. Information given about the past performance of the funds is no guarantee of future performance. No investment decision should be taken without reading the fund prospectus and the key information document available of the fund concerned.

Although the content of the website is based upon information that Lyxor UK consider reliable or comes from sources that Lyxor UK consider reliable, Lyxor UK has not verified such information. Lyxor UK make no representation or warranty as to the accuracy, completeness or adequacy of any information. Any reproduction, disclosure or dissemination of the materials available on the website is prohibited.

Cookies

This website uses cookies to make the website work or improve your user experience. Cookies are small text files that are saved on your computer or device, which are used for several purposes such as detecting preferences and improving site navigation. By continuing to use this website you consent for cookies to be used. For more details, including how to amend your preferences, please read our [Cookies Policy] link to privacy & cookie page.

By clicking on your client type to enter the website, you shall be deemed to have represented to us that you are not a U.S. person and that you are not located in the United States of America, its territories and possessions, and any State of the United States of America and that you are authorised to receive the information to and on this website.

I CONFIRM THAT I HAVE READ AND UNDERSTOOD THE IMPORTANT INFORMATION THAT IS CONTAINED ABOVE AND ACCEPT THE TERMS OF THE PRIVACY AND COOKIES POLICY.

A private investor is a self directed retail client who is making investment decisions on their own behalf in their personal stock broking account, Self Invested Personal Pension or individual savings account

A financial Adviser is a qualified investment professional who provides financial advice or guidance to investors based on their own personal financial situation and risk profile

A professional client is a client that is either a per se professional client or an elective professional client (Note article 4 (1) 12 of Mifid ):

An entity required to be authorised or regulated to operate in the financial markets. The following list includes all authorised entities carrying out the characteristic activities of the entities mentioned, whether authorised by an EEA State or a third country and whether or not authorised by reference to a directive:
- a credit institution
- an investment firm
- any other authorised or regulated financial institution
- an insurance company
- a collective investment scheme or the management company of such a scheme
- a pension fund or the management company of a pension fund
- a commodity or commodity derivatives dealer
- a local
- any other institutional investor
In relation to MiFID or equivalent third country business, a large undertaking, meeting two of the following size requirements on a company basis:
- balance sheet total of EUR 20,000,000
- net turnover of EUR 40,000,000
- own funds of EUR 2,000,000
In relation to business that is neither MiFID or equivalent third country business, a large undertaking meeting either of the following conditions:
- a body corporate (including a limited liability partnership) which has (or any of whose holding companies or subsidiaries has) called up share capital of at least £10 million (or its equivalent in any other currency at the relevant time)
- a large undertaking that meets (or any of whose holding companies or subsidiaries meets) two of the following tests: (i) a balance sheet total of EUR 12,500,000; (ii) a net turnover of EUR 25,000,000; (iii) an average number of employees during the year of 250
- a national or regional government, a public body that manages public debt, a central bank, an international or supranational institution (such as the World Bank, the IMF, the ECP, the EIB) or another similar international organisation.
- another institutional investor whose main activity is to invest in financial instruments (in relation to the firm's MiFID or equivalent third country business) or designated investments (in relation to the firm's other business). This includes entities dedicated to the securitisation of assets or other financing transactions

The above definition is only an extract and is not exhaustive. For further details please refer to the Glossary section of the FSA Handbook: http://fsahandbook.info/FSA/html/handbook/Glossary/P

The information on this website is published by Lyxor Asset Management UK LLP (Lyxor UK), a member of the Société Générale group of companies ("Lyxor UK Group"). Lyxor UK is authorized by Financial Conduct Authority in the UK, under FCA Registration Number 435658.

You should note that an investment in any of these Exchange Traded Funds will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme.

Although information contained herein is from sources believed to be reliable, Lyxor UK makes no representation or warranty regarding the accuracy of any information. Any reproduction, disclosure or dissemination of these materials is prohibited. This site is maintained by Lyxor UK, SG House, 41 Tower Hill, London EC3N 4SG.

GENERAL GUIDANCE

Lyxor UK is the promoter of Lyxor UK Exchange Traded Funds. You cannot trade directly with Lyxor UK.

A number of technical terms are used on this website. If you are in any doubt as to the meaning of such terms, then you should first consult Academy section. There is also a FAQ function which explains some of the terms contained in the website. If you require further clarification please do not hesitate to contact us directly on info@lyxoretf.co.uk, or call 0800 707 6956.

INVESTMENT RISKS

The Lyxor UCITS ETFs described on this website are not suitable for everyone. Investors capital is at risk. Investors should not deal in this product unless they understand, having obtained independent professional advice where necessary, its nature, terms and conditions, and the extent of their exposure to risk. The value of the product can go down as well as up and can be subject to volatility due to factors such as price changes in the underlying instrument and interest rates. If a fund is quoted in a different currency to the index, currency risks exist.

General guidanceLyxor UK is the promoter of Lyxor UK Exchange Traded Funds. You cannot trade directly with Lyxor UK.A number of technical terms are used on this website. If you are in any doubt as to the meaning of such terms, then you should first consult Academy section. There is also a FAQ function which explains some of the terms contained in the website. If you require further clarification please do not hesitate to contact us directly on info@lyxoretf.co.uk, or call 0800 707 6956. INVESTMENT RISKSThe Lyxor UCITS ETFs described on this website are not suitable for everyone. Investors capital is at risk. Investors should not deal in this product unless they understand, having obtained independent professional advice where necessary, its nature, terms and conditions, and the extent of their exposure to risk. The value of the product can go down as well as up and can be subject to volatility due to factors such as price changes in the underlying instrument and interest rates. If a fund is quoted in a different currency to the index, currency risks exist.Prior to any investment in any Lyxor UCITS ETF, you should make your own appraisal of the risks from a financial, legal and tax perspective, without relying exclusively on the information provided by us. We recommend that you consult your own independent professional advisors (including legal, tax, financial or accounting advisors, as appropriate).

SPECIFIC RISKS

Counterparty risk: Through Lyxor UCITS ETFs, investors are exposed to counterparty risk resulting from the use of OTC swaps with Société Générale. Pursuant to the UCITS Directive 2009/65/EC (as may be amended), the exposure of a UCITS to a swap counterparty which is a credit institution for the purpose of the Directive, cannot exceed 10% of the total fund assets. It is recommended that potential investors study the fund prospectus before investing.

As of June, 2015, the long term, senior, unsecured debt obligations of Société Générale were rated A by Standard and Poor’s Ratings Services (S & P) and A2 by Moody’s Investor’s Services Inc (Moody’s). Companies are rated by S&P from AAA (highest rating / most secure) to D (lowest rating / in default / most risky), and by Moody’s from Aaa (highest rating / most secure) to C (lowest rating / in default / most risky).

Liquidity risk: Société Générale is not the only market-maker for Lyxor UCITS ETFs. Société Générale and any other market makers supporting Lyxor UCITS ETFs on exchange must follow the respective London Stock Exchange (LSE) requirements and guidelines. On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the index tracked by the ETF; a failure in the LSE, Société Générale or other market-maker systems; or an abnormal trading situation or event.

PRODUCT SPECIFIC RISK FACTORS

Capital at Risk ETFs are tracking instruments: Their risk profile is similar to a direct investment in the Benchmark Index. Investors’ capital is fully at risk and investors may not get back the amount originally invested. Investments are not covered by the provisions of the Financial Services Compensation Scheme ("FSCS"), or any similar scheme.

Counterparty Risk Investors may be exposed to risks resulting from the use of an OTC (over the counter) Swap with Lyxor UK. Physical ETFs may have Counterparty Risk resulting from the use of a Securities Lending Programme.

Currency Risk ETFs may be exposed to currency risk if the ETF or Benchmark Index holdings are denominated in a currency different to that of the Benchmark Index they are tracking. This means that exchange rate fluctuations could have a negative or positive effect on returns

Replication Risk ETFs are designed to replicate the performance of the Benchmark Index. Unexpected events relating to the constituents of the Benchmark Index may impact the Index provider’s ability to calculate the Benchmark Index, which may effect the ETF’s ability to replicate the Benchmark Index efficiently. This may create Tracking Error in the ETF.

The Benchmark Index of a Lyxor ETF may be complex and volatile. When investing in commodities, the Benchmark Index is calculated with reference to commodity futures contracts which can expose investors to risks related to the cost of carry and transportation. ETFs exposed to Emerging Markets carry a greater risk of potential loss than investment in Developed Markets as they are exposed to a wide range of unpredictable Emerging Market risks.

Liquidity Risk On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the Benchmark Index tracked by the ETF; a failure in the systems of one of the relevant stock exchanges, Lyxor UK or other Market Maker systems; or an abnormal trading situation or event.

The Sub-Funds are recognised Collective Investment Schemes for the purposes of Section 264 of the Financial Services and Markets Act 2000 (the "FSMA") and the Prospectus is available to the general public in the United Kingdom on this website. You are advised that most, if not all, of the protections provided by the United Kingdom regulatory system generally and for UK authorised funds do not apply to recognised funds such as these Sub-Funds

The information on this website is published in the UK by Lyxor Asset Management UK LLP (Lyxor UK), which is authorized by the Financial Conduct Authority in the UK, under FCA Registration Number 435658.

The website is hosted by on Microsoft Azure servers.

This website is subject to French law and English Law

This website is published by Lyxor International Asset Management (LIAM), a simplified joint stock company (société par actions simplifiée) with capital of 1,059,696 euros, listed on the Nanterre Trade and Companies Register under the single identification number 419,223,375 and EPA number 6630Z.

Registered office: Tours Société Générale, 17 cours Valmy, 92800 Puteaux.

Intra-community VAT number: FR 50419223375
Legal representative and director of publication: Lionel Paquin, Chairman, Lyxor International Asset Management.

Managing editor: Nathalie Boschat, Head of the Lyxor Communications Department (Tel.: +33 1 42 14 83 21); e-mail: Nathalie.Boschat@sgcib.com).

This website is hosted on Microsoft Azure servers.
This website is subject to French law.

Professional regulation

LIAM is a French asset management company approved by the AMF (17 place de la Bourse 75082 Paris Cedex 02) under the UCITS (2009/65/EC) and AIFM (2011/31/EU) directives.

Site content

LIAM endeavors to ensure the accuracy and updating of information on this website, and reserves the right to modify the content at any time without notice. LIAM cannot however guarantee its completeness or the absence of modification by a third party (intrusion, virus). Moreover, LIAM accepts no liability in case of difficulty or inability to access the website due to an internet connection problem.

As such, LIAM does not accept liability for any consequential damages such as, but not limited to, losses arising from transactions made on the basis of the information, loss of profit, loss of business, loss resulting from an interruption of service, increased costs of access and information processing.

Similarly, LIAM cannot be held liable for factors beyond its control or any damage that may be suffered by your technical environment, including your computers, software, network equipment (modems, phones, etc.) and any equipment used to access or use the service and/or information.

Finally, LIAM cannot guarantee, and accepts no liability as regards the sequence, accuracy, absence of errors, veracity, currency, merchantability, quality, correctness or non-infringing character and availability of the information on this website.

You undertake to use the information contained on this website for personal, non-commercial purposes.

Information on products and services

The products and services offered by LIAM are not available in all jurisdictions, notably due to regulatory constraints. The terms and conditions relative to products and services (if any) are indicative. The information regarding products and services does not constitute on the part of LIAM or any of its affiliates either an offer to buy, sell or subscribe for financial products or services, or the solicitation of an offer to buy or sell.

LIAM assumes no liability for the accuracy, completeness or adequacy of the information derived from external sources, although the information is obtained from sources deemed reliable.

WHEN PAST PERFORMANCE OR SIMULATED PAST PERFORMANCE IS PRESENTED, THE DATA RELATED THERETO REFER TO PAST PERIODS, AND ARE NOT RELIABLE INDICATORS OF FUTURE RESULTS. THE SAME APPLIES TO VARIATIONS IN HISTORICAL MARKET DATA.

When simulations of future performance are presented, the data relative to these performances are only predictions, and are not a reliable indicator of the future performance of the product. Moreover, where past performance or simulated past performance are based on data expressed in a currency that is not that of the state of residence of the investor, potential gains may increase or decrease based on changes in exchange rates. Finally, where past performance or simulated performances (past or future) are presented, any gains can also be reduced by the effect of commissions, fees or other charges borne by the investor.

Anyone wishing to obtain any of the services or products presented on this website is requested to contact LIAM to inquire about the availability of the service or product in question, and the contractual terms and rates applicable to it.

Subscription of products and services

As part of its legal and regulatory obligations (including those resulting from the European directive on Markets in Financial Instruments – MIFiD), LIAM may be required, depending on the type of products it offers and the classification it assigns you, to verify the suitability or appropriateness of the financial instruments in relation to your hedging or investment objectives, your knowledge and your experience.

Without prejudice to the legal or regulatory obligations borne by LIAM, investors should, before investing in the product or concluding any transaction relating thereto, conduct their own analysis of the product and its risks, especially in respect of legal, tax and accounting aspects, without relying solely on information provided to them. Investors should consult, if they deem it necessary, their own advisors or any other professional on this matter. Subject to compliance with its legal and regulatory requirements, LIAM shall not be held liable for the financial consequences of any nature whatsoever arising from any transaction relating to the product or any investment in the product.

Any online application for subscription to a product or service offered by LIAM is only valid after acceptance by it, and involves the submission of the transaction to contractual and tariff conditions, as well as to French law.

Intellectual property

The entire website is covered by French and international copyright, trademark and, more generally, intellectual property law, both in terms of its form (choice, plan, layout of materials, means of access to data, organization of data, etc.), and in respect of each element of its content (text, images, etc.). The content appearing on the pages of this website is the exclusive property of LIAM. You further undertake not to use such content and not to allow anyone else to use this content for illegal purposes.

Exceptionally, some content (text, images) may be the property of its respective authors.

Any reproduction, distribution or redistribution in whole or in part of the content of this website in any form or by any means whatsoever (including by caching or framing), or any sale, resale, retransmission or distribution to third parties in any way whatsoever is prohibited. Failure to comply with this prohibition constitutes an infringement that may result in civil and criminal penalties.

The hypertext links to other websites do not engage the liability of LIAM, particularly as regards the content of these websites.

LIAM is not responsible for hypertext links pointing to this website, and prohibits any person from establishing such a link without its express consent.

Marketing Restrictions and Implications

Lyxor UCITS compliant Exchange Traded Funds (Lyxor UCITS ETFs) referred to on this website are open ended mutual investment funds (i) established under the French law and approved by the Autorité des Marchés Financiers (the French Financial Markets Authority), or (ii) established under the Luxembourg law and approved by the Commission de Surveillance du Secteur Financier (the Luxembourg Financial Supervisory Committee). Most, if not all, of the protections provided by theUK regulatory system generally and for UK authorised funds do not apply to these exchange traded funds (ETFs). In particular, investors should note that holdings in this product will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme in France.

Index Replication Process

Lyxor UCITS ETFs follow both physical and synthetic index replication process.

Tax

This document has been edited with the free version of the instant HTML edior. Try it here and use it every time for your projects.

IMPORTANT INFORMATION

Any third-party advertising, information and referral buttons containing hyperlinks are not recommendations or endorsements by Lyxor UK or its respective directors, affiliates or employees. The user is referred to the relevant third party for all relevant information, including complete information on that entitys investment adviser or dealer licensing status (if applicable).

All reasonable care has been taken by Lyxor UK to ensure that all statements of fact and opinion contained in the materials provided by a third party are fair, clear and not misleading. Nevertheless, Lyxor UK makes no representation or warranty regarding the accuracy of any third party information and is not responsible for third party content in any way.

UK residents only This site is intended for Professional Clients who intend to trade in Lyxor UK Exchange Traded Funds in the United Kingdom. It is not provided to any person who is a resident of any other country.

You should note that holdings in this product will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme. In particular, the investments can be neither offered nor transferred in the United States.

No investment advice Nothing in this website constitutes advice on the merits of buying, or selling a particular investment or exercising any right conferred by the products described. Lyxor UK does not offer investment advice in respect of these products. Unless you are an institutional or professional investor, you should seek independent financial advice in relation to the products contained in this website.

Accuracy and reliability of information The information in this website is, to Lyxor UKs knowledge, reliable and accurate but this cannot be guaranteed. The views of Lyxor UK reflected in this website may change without notice. Figures included in this website take no account of personal tax liability.

No investment decision should be taken without reading the Legal Documents relating to the particular Exchange Traded Fund concerned. A copy of the Legal Documents may be obtained from Lyxor UK at SG House, 41 Tower Hill, London EC3N 4SG upon request.

Disclosure of interest Lyxor UK or its associates may from time to time have a position, or material interest in the products described in this website or the investments underlying them.

Generally Lyxor UK will be the only market maker in the Exchange Traded Funds discussed and will or may have provided significant advice in relation to the Exchange Traded Funds and the investments underlying them.

This is the privacy and cookies policy for the Lyxor ETF website, which is operated by Lyxor Asset Management UK LLP (Lyxor UK).

Collection of your information

Lyxor UK may obtain personal information about you during the course of your participation with the Lyxor ETF website, sometimes through the use of on-line or off-line forms.

Use of your information

The information you voluntarily provide us through this website or email (which may include your name, company, address and contact details such as your telephone number, email address or fax number) will be used for the following purposes:

to send you information and updates about products on the Lyxor ETF website;
to satisfy your requests, such as publications or information relating to Lyxor ETF;
to respond to your query if you have emailed us with an enquiry (for example, in relation to any Lyxor ETF or a forthcoming publication or event);
to send you further information and marketing materials about our services, products, publications, events or keep you informed through our periodic newsletters provided that you have indicated that you are happy to be contacted for these purposes.

Who do we share your information with?

We may (to the extent necessary) pass your personal information to members of the Societe Generale Group and Lyxor UK’s partners, providers, and subcontractors (for whom we remain responsible in this regard) who assist us in providing the services we offer, such as fulfilling requests for information, receiving and sending communications, updating marketing lists, analysing data, providing support services or in other tasks from time to time. Our agents and contractors will only use your information to the extent necessary to perform their functions.

In the event that we undergo re-organisation or are sold to a third party, you agree that any personal information we hold about you may be transferred to that re-organised entity or third party.

We may disclose personal information about you if required to do so by law enforcement or other government or regulatory bodies and their officials or to third parties in connection with an investigation of fraud, intellectual property infringement, breach of any law or other activity that is illegal or which may expose us to legal liability, or in order to protect our rights and property.

International Transfers

Your personal data may be processed by staff operating outside the European Economic Area ("EEA") or your local jurisdiction who work for us or for one of our suppliers chosen for their expertise in certain areas. This may, for example, happen if one or more of our servers are from time to time located in a country outside the EEA or one of our service providers is located in a country outside the EEA. If we transfer your information outside the EEA in this way, we will take steps to ensure that your privacy rights continue to be protected

What are Cookies and how are they used?

This policy explains how our website uses Cookies. It forms part of the important information and the terms and conditions of our website.

A cookie is a small file, typically of letters and numbers, downloaded on to a device when the user accesses certain websites. Cookies allow this website to recognise your computer throughout your session.

The Lyxor ETF website uses a combination of the types of cookies listed below:

What cookies do we use?	What is the purpose of the Cookie?	What is the shelf life?
JSESSIONID	These cookies are used to customise the visitor experience and save the user preferences by linking it to the website account.	Session
_ga	This cookie name is asssociated with Google Universal Analytics - which is a significant update to Google's more commonly used analytics service. This cookie is used to distinguishes unique users by assigning a randomly generated number as a client identifier.	2 Years
_gat	This cookie name is associated with Google Universal Analytics, according to documentation it is used to throttle the request rate - limiting the collection of data on high traffic sites.	10 minutes
disclaimerinstit	These cookies are used to remember if the visitor has accepted the disclaimer for institutional profile	1 Month

How do I set my cookie preferences?

Most web browsers allow some control of most cookies through the browser settings.

You may also delete and block all cookies from the Lyxor ETF Website but parts of the Lyxor ETF website may not work.

To find out more about cookies, including how to see what cookies have been set and how to manage and delete them, visit www.aboutcookies.org or www.allaboutcookies.org.

Other websites

The Lyxor ETF website may, from time to time, contain links to and from the websites of our partners, advertisers or other websites providing relevant information. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

Your rights of access and rights to modify your personal information

You have the right to ask for a copy of the personal information we hold about you in our records by writing to Lyxor ETF, SG House, 41 Tower Hill, London EC3N 4SG. Alternatively, you can email info@lyxoretf.co.uk.

You also have the right, at any time, to object to the processing of your personal information, to require us to correct any inaccuracies in your information or to remove such information or to request us not to process your personal data for marketing purposes.

You should contact us at the above address if you wish to do any of these things. We will retain in our files certain information you have requested us to remove in order to resolve future disputes, to troubleshoot problems or to enforce the Terms. We will retain data only for the duration of the purpose for which it was obtained and may need to retain some details about you after your relationship with Lyxor UK has ended, for example for legal and regulatory purposes.

What to do if you wish to stop hearing from us

If you no longer wish to hear from Lyxor ETF about opportunities or if any of your details change, please inform us by email at info@lyxoretf.co.uk.

Changes to our privacy policy Ancre

Any changes we may make to our privacy policy in the future will be posted on this page and, where appropriate, may be notified to you by e-mail.

By continuing to browse the site, you are agree on the use of cookies to track the number of visits.To know more about cookies policy:click here

Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)

HLTW Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)

Capitalisation

Smart Beta

Sector

Currency Hedged

Style, Small/Mid Caps

Leveraged, Short and Double Short

World

Developed Market

Equity

Latest NAV :

358.7989 USD

Data as of 05/12/2019, Source: Lyxor International Asset Management

Performance YTD:

19.22%

Total return as of 04/12/2019

Asset Under Management

404.1m USD

ISIN

LU0533033311

TER

0.3%

Dividend Treatment

Capitalisation

Nav History

Prospectus

KIID

Factsheets

ESG

Documento di Quotazione

Overview Product Performance Index Information Fund Holdings Documents

Investment Objective

The Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD) is a UCITS compliant exchange traded fund that aims to track the benchmark index MSCI Daily TR World Net Health Care USD.
The MSCI Daily TR World Net Health Care USD is a free float-adjusted market capitalization index that is designed to measure the investable universe and the performance of the Health Care listed companies. It is designed to cover large and mid cap securities and is constructed using the MSCI Global Investable Market Index (GIMI) methodology to match the size, liquidity and minimum free float criteria.
Lyxor ETFs are efficient investment vehicles listed on exchange that offer transparent, liquid and low-cost exposure to the underlying benchmark index.

Main Fund Characteristics

ISIN LU0533033311

UCITS Yes

Base currency USD

Assets Under Management 404.1m USD

Total Expense Ratio 0.3%

Dividend Treatment Capitalisation

EU-SD Status Out of Scope

Fund Type SICAV

Domicile Luxembourg

Replication Method Indirect (Swap Based)

Umbrella AUM 36,617m USD

ISA Yes

SIPP Yes

German tax transparency Yes

Financial Year End 31/12/2019

Portfolio Managers Raphaël Dieterlen, Sebastien Foy

Swap Counterparty Société Générale

Full property of the assets Yes

UKFRS Yes

Inception Date 18/08/2010

Minimum investment 1 Share

DISCLAIMER: This fund includes a risk of capital loss. Investors therefore may not recover all or part of their initial investment. The redemption value of this fund may be less than the amount initially invested. In a worst case scenario, investors could sustain the loss of their entire investment.
Be sure to read carefully the Key Investor Information document, and the “risk factors” section of a fund’s performance to better understand the risks involved.

Trading Information

Exchange	Ticker Bloomberg	Listing Currency	Currency Hedged	Listing Date	Dividend Policy	ADV 3M	ISIN	Fund AUM in CCY
LSE	HLTW LN	USD	-	27/09/2010	Capitalisation	31,182USD	LU0533033311	404.1m USD
SIX Swiss Ex	LYHLTW SW	USD	-	23/11/2010	Capitalisation	25,712USD	LU0533033311	404.1m USD
Borsa Italiana *	HLTW IM	EUR	-	24/09/2010	Capitalisation	275,754EUR	LU0533033238	364.5m EUR
Xetra *	LYPE GY	EUR	-	29/09/2010	Capitalisation	192,536EUR	LU0533033238	364.5m EUR
Euronext *	HLTW FP	EUR	-	22/10/2010	Capitalisation	92,992EUR	LU0533033238	364.5m EUR

* Related Shareclasses

Market Makers

Commerzbank

Flow Traders

Optiver

Société Générale

Susquehanna

Data provided by relevant exchanges

Passporting Information

Luxembourg

Germany

Netherlands

France

Switzerland

Sweden

Finland

Singapore

Czech Republic

Korea

Data as of04/12/2019, Source: Lyxor International Asset Management

Performance : The figures relating to [past performances / simulated past performances / past performances and simulated past performances] refer or relate to past periods and are not a reliable indicator of future results. This also applies to historical market data."

Performance Chart

AUM Evolution

Performance Chart

Performance

Product	YTD	1M	3M	6M	1Y	3Y	5Y	ALL
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD) ETF	19.22%	4.65%	10.11%	13.96%	11.13%	49.27%	39.75%	203.19%

MSCI Daily TR World Net Health Care USD Benchmark
Market Cap Index

Data as of04/12/2019, Source: Lyxor International Asset Management

Product	2A	3A	4A	5A
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD) ETF
MSCI Daily TR World Net Health Care USD Benchmark
Market Cap Index

Data as of04/12/2019, Source: Lyxor International Asset Management

NAVs History

From

Date	NAV	Currency	Fund AUM
No records found.

Date	NAV	Currency	Fund AUM
04/12/2019	358.5506	USD	404.1m USD
03/12/2019	356.0132	USD	399.7m USD
02/12/2019	356.6148	USD	399.2m USD
29/11/2019	358.2059	USD	401m USD
28/11/2019	359.3986	USD	402.3m USD
27/11/2019	359.2282	USD	400.7m USD
26/11/2019	357.9095	USD	399.2m USD
25/11/2019	357.5627	USD	398.8m USD
22/11/2019	353.4576	USD	394.2m USD
21/11/2019	352.5883	USD	392.1m USD

Dividend History

Date	Amount	Currency
No records found.

Date	Amount	Currency
This fund does not distribute any dividend.

Top Ten Index Constituents

Index Information

Full Name	MSCI Daily TR World Net Health Care USD
Index Type	Performance
Index Bloomberg Ticker	NDWUHC
Index Currency	USD
Number of Index Components	147
Further Informations	https://www.msci.com/
Dividend Yield (%)	1.84

Index Composition Breakdown

Country Breakdown

Data as of04/12/2019, Source: Lyxor International Asset Management

This ETF uses synthetic replication to track the performance of the index. As such, the holdings of the ETF may vary from that of the benchmark index.You can read more about our approach to replication in our

pragmatic guide to replication.

Top 10 Fund Holdings

Name	Currency	Quantity	Weight %
BANCO SANTANDER SA	EUR	5,958,141	5.83%
SYDNEY AIRPORT	AUD	3,210,739	4.85%
AGEAS	EUR	285,221	4.23%
SIEMENS AG-REG	EUR	120,974	3.93%
BNP PARIBAS	EUR	255,576	3.54%
ING GROEP NV-CVA	EUR	1,226,980	3.48%
LULULEMON ATHLETICA INC	USD	62,189	3.48%
CENTRAL JAPAN RAILWAY CO	JPY	61,296	3.08%
IBERDROLA SA	EUR	884,743	2.11%
AXA SA	EUR	303,002	2.05%

Swap Information

Basket adjustment	The basket is daily adjusted to the fund outstanding level
Counterparty risk Level	N/A From 1st March 2017, the European Market Infrastructure Regulation («EMIR») requires certain EU counterparties, including undertakings for collective investment in transferable securities («UCITS»), to put in place risk mitigation procedures prior to entering into OTC derivatives trades. This regulation obliges both parties to a swap transaction to exchange collateral in order to reduce any counterparty exposure to zero allowing for a minimum transfer amount of €500,000.
Swap Counterparty	Société Générale
Date	04/12/2019

1 week moving average of counterparty risk level

Counterparty risk level at daily adjustment time

Swap Price Component

Although past performance is no indicator of future performance, you can get an estimation of the swap price component over the last 12 months by adding the TER to the realized Tracking Difference. the price of being long the index and short the basket of securities held by the ETF (ie. the spread applicable to the index performance provided by the swap counterparty) can be understood as the swap price component. The latter can be positive or negative, depending on the following factors: Read more

Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)
1Y Tracking Difference	-0.09%
Total Expense Ratio	+ 0.3%
Swap price component estimation	= 0.21%

Holding Composition Breakdown

Country Breakdown

Data as of04/12/2019, Source: Lyxor International Asset Management

Fund related documents

ETF Name	Type	Language	Publication Date	Size
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)	Factsheets	English	31/10/2019	256 Ko
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)	Prospectus	English	11/09/2019	7088 Ko
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)	KIID	English	19/02/2019	193 Ko
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)	Annual Reports	English	31/12/2018	13457 Ko
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)	UKRFS Reports	English	15/03/2019	262 Ko
Lyxor MSCI World Health Care TR UCITS ETF - Acc (USD)	ESG	English	31/10/2019	271 Ko

Notice to Investors in Asia-Pacific Region

This document is prepared for and intended to be distributed in Asia-Pacific Region solely to sophisticated and professional clients. You should thereforebe appropriately qualified as a professional, accredited, wholesale, expert or institutional investor (however defined in your local jurisdiction). It is distributed by licensed affiliates of Societe Generale (“SG”) which is a French credit institution (bank) authorised by the Autorité de Contrôle Prudentiel (the French Prudential Control Authority) in accordance with applicable regulations and SG’s internal policy. You should be aware that local regulations may not allow this document to be distributed from your local SG licensed affiliate, but may allow it to be distributed from an offshore branch or affiliate under certain circumstances. If in any doubt, you should always determine which licensed affiliate is responsible for distributing this document to you by contacting SG. You should also be aware that financial products or services referred to may not be sold, bought or subscribed to if you do not qualify in your local jurisdiction. Always ensure that you contact and deal through appropriately licensed entities if you wish to purchase any such products or services.

For Investors Receiving This Document From SG Securities (HK) Limited: This document is distributed to you by SG Securities (HK) Limited (CE: AAD941) ("SG") as an activity that is wholly incidental to its carrying out of a regulated activity for which it is already licenced. Details of SG's licence can be provided upon request.

SG Securities (HK) Limited (“SGSHK”) has been appointed by Lyxor Asset Management and Lyxor International Asset Management (“Lyxor”) to promote the funds launched by Lyxor. Investors [and prospective investors] should note that a service fee may be paid by Lyxor to SGSHK for its services.

For Recipients Where This Document is Distributed by Societe Generale, Hong Kong Branch: This document is issued solely to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. If this document is distributed to you by SG Securities (HK) Limited (CE: AAD941) (“SGHK”), the details of SGHK’s licence can be provided upon request.

For Recipients in Singapore: This document is distributed by MAS licensed representatives of Société Générale, Singapore Branch and may only be provided to institutional investors, as defined in Section 4A of the Securities and Futures Act. If you wish to discuss this document or effect transactions in any security discussed herein, you should do so with or through MAS licensed representatives of Société Générale, Singapore Branch. If you are an accredited investor or expert investor, please be informed that in our dealings with you, we are relying on certain exemptions to the Financial Advisers Act (“FAA”) - (1) the exemption in Regulation 33 of the Financial Advisers Regulations (“FAR”), which exempts us from complying with Section 25 of the FAA on disclosure of product information to clients; (2) the exemption set out in Regulation 34 of the FAR, which exempts us from complying with Section 27 of the FAA on recommendations; and (3) the exemption set out in Regulation 35 of the FAR, which exempts us from complying with Section 36 of the FAA on disclosure of certain interests in securities.

For Documents Distributed in China from Offshore (as a Result of a Reverse Enquiry): This document has been prepared and distributed by Societe Generale as a result of a reverse enquiry by you. Societe Generale (China) Limited has not been involved with the preparation or distribution of this document. Any products or services that may be mentioned in this document are subject to laws and regulations and regulator’s requirements in China and may not be able to be provided in China.

Notice for Documents Distributed in Taiwan: This document is to present to you as a result of reverse enquiry and may only be distributed to “professional institutional investors” within the meaning provided in the applicable regulations in Taiwan. The product(s) or service(s), if any, mentioned in this document, have not been registered with or approved by Taiwan competent authorities and are not regulated by Taiwan laws and regulations.

For Recipients to Korean Investors: This document is distributed by SG Securities (HK) Limited outside Korea and intended only for Korean financial institutions holding the dealing or brokerage business license under the Financial Investment and Capital Market Act of Korea and the Enforcement Decree thereof. SG Securities (HK) Limited is regulated by the Securities & Futures Commission under Hong Kong laws. The product mentioned in this document may not be eligible or suitable for all types of investors. This document is not intended for private customers.

Notice to Australian Investors: This document is distributed in Australia by SG Securities (HK) Limited (SGHK). Under ASIC Class Order [CO 03/1103], SGHK is exempt from the requirement to hold an Australian financial services licence for the provision of its financial services to you. SGHK is authorised and regulated by the Securities and Futures Commission of Hong Kong under the laws of Hong Kong which differ from Australian laws. This document is provided to you on the basis that you are a 'wholesale client' within the meaning of section 761G of the Corporations Act 2001 (Cth).

Website Sections

Useful linksAbout Lyxor ETF Credits Legal Notice Key risks Privacy and cookies

08007076956

info@lyxoretf.co.uk